Longevity: Selank (Anxiolytic Tuftsin Analogue — BDNF & GABA Modulation)

How a seven-amino-acid peptide from Russian pharmaceutical research addresses anxiety, stress and cognitive deficits

Selank is a synthetic heptapeptide (seven amino acids) developed as a stable analogue of the body's own immunomodulator tuftsin. It combines three pharmacological properties in a single molecule: anxiolytic (anxiety-reducing), nootropic (cognition-enhancing) and immunomodulatory. It was developed at the Institute of Molecular Genetics of the Russian Academy of Sciences (IMG RAN) and is approved in Russia under the brand name Selank (solution for intranasal administration) as an anxiolytic. Its mechanisms of action include modulation of Brain-Derived Neurotrophic Factor (BDNF), influence on the GABA system and inhibition of the enzyme enkephalinase — three targets that distinguish Selank from classical benzodiazepines and barbiturates.

Mechanism: Four Independent Levels of Action

Selank is pharmacologically unusual in that it combines four different targets — a multi-target peptide in the spirit of modern network pharmacology:

1. Tuftsin Analogue: Stabilization of Immune Signaling

Tuftsin (Thr-Lys-Pro-Arg) is a naturally occurring tetrapeptide that is enzymatically released from the Fc fragment of immunoglobulin G (IgG) and acts via the tuftsin receptor (Fcγ-receptor-like) on macrophages, neutrophils and lymphocytes. It promotes phagocytosis, antigen presentation and cytokine balance.

Selank (Thr-Lys-Pro-Arg-Pro-Gly-Pro) carries the complete tuftsin motif as its N-terminal sequence and is stabilized against proteolytic degradation by the additional C-terminal amino acids (Pro-Gly-Pro). In this way, Selank mimics tuftsin signaling without being degraded as quickly — and thereby reaches central effects on monocytes/macrophages and microglial cells in the brain (PMID 30255741).

2. BDNF Modulation in Hippocampus and Prefrontal Cortex

Brain-Derived Neurotrophic Factor (BDNF) is the central neurotrophic protein for synaptic plasticity, learning, memory and mood regulation. Reduced BDNF levels are a consistent finding in depression, anxiety disorders and PTSD. Selank normalizes stress-induced reductions in BDNF levels — demonstrated in a rat model with ethanol-induced memory deficits (PMID 31625062): Selank administration increased BDNF concentration in hippocampus and prefrontal cortex and protected against ethanol-induced cognitive impairment. This distinguishes Selank from classical anxiolytics, which decrease BDNF (such as benzodiazepines with chronic administration).

3. GABA-A Receptor Modulation

Selank is not a direct GABA-A agonist like benzodiazepines or barbiturates, but acts in a modulatory fashion on the GABAergic system — presumably via influencing the expression of GABA-A receptor subunits and indirect enhancement of GABAergic transmission. A comprehensive review in the Journal of Clinical Pharmacology (2021, PMID 34396551) classifies Selank alongside phenibut, flunitrazepam and GHB as a sedatively-hypnotically acting GABA modulator, but emphasizes the markedly more favorable safety and dependence profiles compared with the other three substances. Selank does not produce the tolerance development typical of benzodiazepines in animal models and shows no muscle-relaxant or respiratory-depressant effects at anxiolytically active doses.

4. Enkephalinase Inhibition

Enkephalinase (neprilysin) is the main enzyme for the degradation of endogenous enkephalins (methionine-enkephalin, leucine-enkephalin). Selank inhibits this enzyme — possibly indirectly via the influence on gene expression. The consequence is a prolonged half-life of the body's own opioid peptides, which are involved in pain modulation, emotional resilience and stress coping. This component partly explains the anxiolytic and mildly mood-brightening effect without addiction potential.

5. Pharmacokinetics and Route of Administration

Selank is administered clinically intranasally (0.15% solution, standard dosage 250–500 µg per dose, 2 to 3 times daily). The intranasal route was chosen because the peptide would be rapidly degraded orally by gastric acid and intestinal peptidases — the nasal mucosa, on the other hand, allows direct absorption into the systemic circulation and, via the olfactory route, a certain direct access to the CNS bypassing the blood-brain barrier.

The plasma half-life is in the range of a few hours — typical for small peptides that are eliminated renally. No cytochrome P450 interactions are expected, since Selank as a peptide is not metabolized via hepatic phase I enzymes. Thus pharmacokinetic interactions with classical psychotropic drugs (SSRI, SNRI, benzodiazepines) are limited to additive-synergistic sedative effects — metabolic interference is unlikely.

The pharmacokinetic profile makes Selank a particularly predictable active substance for patients with comedications — an advantage over benzodiazepines, whose cytochrome-mediated metabolism displays strong genetic polymorphisms (CYP3A4, CYP2C19) and routinely leads to clinically relevant drug interactions.

An interesting observation from the Russian usage data is the lack of accumulation with regular intranasal administration over several weeks — consistent with the short plasma half-life and the renal clearance. This differentiates Selank pharmacokinetically from substances such as phenazepam or phenibut, whose long duration of action and partly uncontrolled accumulation are regarded as safety risks.

Clinical Evidence

The evidence base for Selank relies on preclinical studies (rat models, hippocampal slice preparations) as well as clinical observations from Russian application practice. Published randomized controlled human studies in the Western sense are scarce — most data come from Russian sources and are partly difficult to access. Below are the six central peer-reviewed publications from PubMed:

1. Selank in Opioid Withdrawal (2022, Bull Exp Biol Med)

A preclinical study (PMID 36322304) showed that Selank attenuates aversive signs of morphine withdrawal in a rat model. Rats chronically treated with morphine showed typical withdrawal symptoms after naloxone provocation; Selank administration significantly reduced these behavioral markers. The mechanism was linked to the modulation of serotonergic and GABAergic neurotransmission as well as BDNF preservation. This study is relevant because it confirms Selank's anxiolytic effect in a particularly severe stress model.

2. Selank Compared with GABA Modulators (2021, J Clin Pharmacol)

A comprehensive review (PMID 34396551) classifies Selank as a sedative-hypnotic agent with GABA action — alongside flunitrazepam, GHB (gamma-hydroxybutyrate) and phenibut. The review emphasizes that Selank, despite its GABAergic action, causes no clinically relevant respiratory depression, shows no tolerance development at standard dosages and does not trigger classical benzodiazepine dependence. This special pharmacological position makes Selank interesting for psychiatrists and stress physicians.

3. Functional Connectomics (2020, Dokl Biol Sci)

A study on functional connectivity (PMID 32342318) compared the effects of Selank and Semax (a related nootropic peptide) on brain networks. Using functional imaging, altered connectivity patterns were identified in stress and attention networks — particularly in the region of the anterior cingulate cortex and the insula, which are regularly hyperactive in anxiety disorders. The study provides a neuroscientific framework for the observed anxiolytic and cognition-enhancing effect.

4. BDNF Mechanism in Ethanol-Induced Memory Deficit (2019, Bull Exp Biol Med)

A key mechanistic study (PMID 31625062) investigated the effect of Selank on ethanol-induced cognitive deficits in a rat model. Ethanol is known to lower BDNF expression in hippocampus and prefrontal cortex. Selank administration normalized BDNF levels and protected against the spatial memory deficit. The mechanism involves upregulation of BDNF mRNA and stabilization of the TrkB signaling pathway — a profile similar to that of classical antidepressants (SSRI, ketamine), but without their side-effect profile.

5. Molecular Aspects of Heptapeptide Activity (2018, Protein Pept Lett)

A detailed review on structure-activity relationships (PMID 30255741) summarizes the molecular basis of Selank's action: binding to the tuftsin receptor, modulation of intracellular signaling cascades (cAMP, MAPK/ERK), influence on the gene expression of neurotrophic factors (BDNF, NGF). The review emphasizes that even minimal sequence modifications to the heptapeptide drastically alter biological activity — an indication of precise receptor interaction.

6. Hippocampal Synaptic Activity (2017, Bull Exp Biol Med)

An electrophysiological study (PMID 28361410) investigated the effect of Selank on spontaneous synaptic activity in CA1 neurons of the hippocampus (rat brain slice preparation). Selank altered the frequency and amplitude of spontaneous inhibitory and excitatory postsynaptic currents — direct evidence of the modulatory effect on hippocampal networks. The hippocampus is central for memory, fear consolidation and stress regulation.

Comparison Table: Where Does Selank Stand in the Spectrum of Russian Anxiolytics/Nootropics?

Sources: PMID 34396551, 30255741, 32342318; Russian pharmaceutical registers. Semax is discussed in detail in a separate article in this series.

Side Effects & Safety

The available safety data from Russian application and from animal studies paint an overall favorable picture — Selank differs markedly from classical anxiolytics:

• Acute side effects (rare): mild drowsiness in the first days of treatment, transient headaches, local irritation of the nasal mucosa (with intranasal administration), occasionally mild dry mouth.
• No respiratory depression at clinically used doses — a crucial difference from benzodiazepines and barbiturates (PMID 34396551).
• No muscle-relaxant effect at anxiolytically active doses.
• No indication of tolerance development or classical dependence in animal studies over several weeks of treatment.
• No teratogenicity in animal experimental studies, but insufficient human data for pregnancy and breastfeeding.
• Withdrawal symptoms: Not systematically investigated in the available studies. Due to the GABAergic component and the enkephalinase inhibition, a theoretical rebound phenomenon on abrupt discontinuation after long-term use cannot be ruled out — a stepwise reduction is advisable.

Important caveat: Most of the available safety data come from small Russian studies without modern GCP standards (Good Clinical Practice). Western phase 2/3 studies with adequate power, clear endpoints and independent data analysis do not exist as of 2026.

Practical Implications

As of June 2026, Selank is neither approved as a medication nor as a dietary supplement in Europe, the USA or Germany. The following points are relevant for interested users:

• Russian availability: In Russia, Selank is sold in pharmacies under the same brand name (intranasal drops, 0.15%; usual dose 250–500 µg, 2 to 3 times daily). A medical prescription is required.
• Gray market in EU/USA: Various online providers (in particular via Russian mail-order pharmacies or "research peptide" vendors) offer Selank lyophilisates or solutions. These products are not tested for purity, dosing accuracy or sterility and are not subject to any pharmaceutical quality control. A not insignificant proportion of "research grade" peptides from the internet show deviations from the declared sequence, impurities or inconsistent dosages.
• Individual considerations: Self-administration outside Russia is not advisable — neither legally nor pharmacologically-toxicologically. Persons with diagnosed anxiety disorder, PTSD or chronic stress should prefer established therapies (cognitive behavioral therapy, SSRI/SNRI, established anxiolytics).
• Stress management alternatives: Until Western approval, meditation, endurance exercise, sleep optimization and cognitive behavioral therapy are the most effective evidence-based means of increasing BDNF and building stress resilience — all with documented safety and without gray market risk.

Outlook: Clinical Translation Outside Russia

The translational hurdle for Selank is less pharmacological than regulatory and commercial:

• Pharmacological suitability: The multi-target mechanisms (BDNF, GABA, enkephalinase, tuftsin) are consistently documented; the safety profile from animal studies and Russian application is favorable. From a scientific perspective there is no reason why Selank could not be made accessible to Western patients as well.
• Regulatory hurdles: Western approval would require GMP-compliant manufacturing, complete toxicology packages according to ICH guidelines and phase 1–3 studies — investments in the low three-digit million euro range. For a non-patentable or weakly patentable heptapeptide, this is commercially difficult to realize. Structural variants with increased patentability would be a possible strategy.
• Indication areas with need: PTSD treatment (post-traumatic stress disorder), treatment-resistant GAD (generalized anxiety disorder), opioid withdrawal support, cognitive deficits after viral encephalitis — all fields in which Western standard therapies are only partially effective.
• Research trend: The growing interest in peptidergic therapeutics — driven by GLP-1 agonists (semaglutide, tirzepatide) and neurotrophic peptides — could also bring new attention to Selank analogues.
• Relation to tuftsin itself: The natural tuftsin tetrapeptide (Thr-Lys-Pro-Arg) is also being further researched, for example in the context of immunodeficiencies and tumor immunotherapy (e.g., PubMed indexings on tuftsin–endothelial cell interactions). Selank data indirectly provide insights into tuftsin signaling pathways.
• Longevity interface: BDNF is not only a mood and cognition mediator, but also a survival factor for hippocampal and cortical neurons. Animal studies show that elevated BDNF levels promote hippocampal neurogenesis — a process that continues into adulthood and is associated with cognitive reserve in old age. Selank-like BDNF stabilization could therefore theoretically have neuroprotective long-term effects that go beyond acute anxiolysis — this hypothesis is currently not clinically validated, but is a plausible translational starting point.
• Synergy with lifestyle interventions: Known BDNF boosters are endurance exercise, sleep and caloric restriction. Selank could act in combination with these lifestyle factors as a pharmacological amplifier, without suppressing physiological adaptation processes — a theoretical advantage over benzodiazepines, which are known to block training-induced BDNF increases.

Conclusion

Selank is a pharmacologically fascinating heptapeptide, developed as a stable analogue of the body's own tuftsin and used in Russia for over a decade as an anxiolytic and nootropic. The strength of the active substance lies in its multi-target profile: BDNF upregulation in hippocampus and prefrontal cortex (PMID 31625062), modulation of GABAergic transmission without respiratory depression (PMID 34396551), enkephalinase inhibition and direct action on hippocampal synapses (PMID 28361410). In animal models, Selank shows anxiolytic effects even under extreme stress conditions such as morphine withdrawal (PMID 36322304) and ethanol-induced cognitive impairment.

For longevity medicine, Selank is indirectly relevant: chronic stress and untreated anxiety disorders accelerate biological aging via allostatic load, telomere shortening, BDNF suppression and inflammaging. A pharmacological tool that addresses these pathways without dependence or respiratory depression risk would have a clear place in preventive stress medicine — provided Western phase 2/3 data confirm the results from Russian sources.

Until then, Selank remains an experimental active substance without approval outside Russia. Self-administration via gray market sources is neither legally nor pharmacologically advisable. The coming years will show whether Western pharmaceutical companies or academic consortia will take on the translational risk to develop Selank — or a structurally related analogue — in Western indications.